Inflammation plays a key role in the pathogenesis of diabetic retinopathy (DR), leading to alterations in the blood–retinal barrier and increased vascular permeability. Many anti-VEGF medications are now available for the treatment of DR, but response to these medications is not as robust in patients with diabetic macular oedema. Newer biologic agents are currently under study to improve the treatment of DR. These have shown promising results to both decrease the treatment burden of intravitreal injections and improve visual outcomes for diabetic patients.
Keywords
Chemokines, Cytokines, Diabetic Retinopathy, Drug Therapy, Inflammation.
User
Font Size
Information